Lactobacillus rhamnosus GG ： Antibiotic-Associated Diarrhea (AAD)
AMeta-analyses demonstrate LGG reduces AAD incidence by 42-49%. Most effective when started within 48 hours of antibiotic initiation and continued 7 days after completion.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dlactobacillus\u002Drhamnosus\u002Dgg\u0026condition\u003Dantibiotic\u002Dassociated\u002Ddiarrhea';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
A
結論
Meta-analyses demonstrate LGG reduces AAD incidence by 42-49%. Most effective when started within 48 hours of antibiotic initiation and continued 7 days after completion.
Key Study Findings
Observational Study
n=279
Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …
Dose: None
vs: None
Outcome: Probiotic prescribing habits of Italian PCPs
効果: L. rhamnosus GG used by 91.8%
None
対象集団: Italian primary care pediatricians
Other
Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …
Dose: None
vs: None
Outcome: Clinical guideline recommendations for pediatric GI
効果: None
None
対象集団: Pediatric patients with GI disorders
Controlled Clinical Trial
n=24
2 weeks
Protective Effect of Probiotics on Cardiac Damage in Experimental Sepsis Model Induced by Lipopolysaccharide in …
Dose: 10^9 CFU/day for 14 days
vs: LPS-only group (no probiotics)
Outcome: Cardiac damage markers (CK-MB, cTn-I, cytokines)
効果: None
p<0.05 to <0.001
対象集団: Male Wistar albino rats with LPS-induced sepsis
Review
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Dose: None
vs: None
Outcome: None
効果: None
None
対象集団: Pediatric population
Randomized Controlled Trial
Double-blind
A Multi-Hospital Comparative Study on the Efficacy of Probiotics Versus Placebo in Preventing Antibiotic-Associated Diarrhea …
Dose: Probiotics (multi-strain)
vs: Placebo
Outcome: Antibiotic-associated diarrhea incidence
効果: None
None
対象集団: Adult patients receiving antibiotics
Review
Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review.
Dose: S. boulardii CNCM I-745
vs: Placebo or standard care
Outcome: AAD prevention and pediatric gastroenteritis
効果: None
None
対象集団: AAD and gastroenteritis patients (review)
Key Statistics
20
研究数
4000
参加者数
↑
Positive
A
グレード
Referenced Papers
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Review
Journal of gastroenterology …
2025
10 件の引用
Medicina (Kaunas, Lithuania)
2025
1 件の引用
Antibiotics (Basel, Switzerland)
2025
Boletin medico del …
2025
Cureus
2024
1 件の引用
Cureus
2023
19 件の引用
Archivos argentinos de …
2022
23 件の引用
Canadian journal of …
2022
6 件の引用
International journal of …
2020
32 件の引用
Pediatric gastroenterology, hepatology …
2020
20 件の引用
Pharmacological research
2018
132 件の引用
A practical guide for probiotics applied to the case of antibiotic-associated diarrhea in The Netherlands.
Meta-Analysis
BMC gastroenterology
2018
80 件の引用
United European gastroenterology …
2018
66 件の引用
Probiotics and antimicrobial …
2018
26 件の引用
World journal of …
2017
68 件の引用
Journal of pediatric …
2016
233 件の引用
Digestive diseases (Basel, …
2016
37 件の引用
The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts.
Systematic Review
Paediatric drugs
2015
122 件の引用
Journal of clinical …
2015
35 件の引用
Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children.
Review
Nutrition in clinical …
2015
31 件の引用
Nutricion hospitalaria
2015
5 件の引用
Medycyna wieku rozwojowego
2012
1 件の引用
Current opinion in …
2009
82 件の引用
Advances in biochemical …
2008
535 件の引用
The Journal of …
2007
265 件の引用
The American journal …
2006
918 件の引用
Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea.
Review
Journal of clinical …
2006
112 件の引用
Inflammation
2002
37 件の引用
The American journal …
2001
648 件の引用
Inflammation
2001
101 件の引用
The Journal of …
1999
559 件の引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
一般的な使用量
- general:
- 10-20 billion CFU/day
- ibssupport:
- 10 billion CFU/day for 4-8 weeks
- aadprevention:
- 10-20 billion CFU/day (start with antibiotic, continue 7 days after)
上限量： Generally well-tolerated up to 40 billion CFU/day in clinical trials
研究で検討された用量
| 用量 | 期間 | 効果 | N |
|---|---|---|---|
| None | -- | Mixed | 279 |
| None | -- | Positive | -- |
| 10^9 CFU/day for 14 days | 2 weeks | Positive | 24 |
| None | -- | Mixed | -- |
| Probiotics (multi-strain) | -- | Positive | -- |
| S. boulardii CNCM I-745 | -- | Positive | -- |
| None | -- | Positive | -- |
| Twice daily | -- | Neutral | 2650 |
推奨摂取タイミング： On an empty stomach or 30 minutes before meals for optimal survival
Safety & Side Effects
報告されている副作用
- ⚠ Mild gas and bloating during initial use (usually resolves in 1-2 weeks)
- ⚠ Rare reports of bacteremia in severely immunocompromised individuals
- ⚠ Occasional loose stools during adjustment period
- ⚠ Very rare: systemic infection in critically ill patients with central venous catheters
既知の相互作用
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Immunosuppressants (theoretical risk of infection in immunocompromised patients)
- ● Antifungals (no known interaction but may affect gut flora balance)
耐容上限摂取量： Generally well-tolerated up to 40 billion CFU/day in clinical trials
サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
Frequently Asked Questions
Does Lactobacillus rhamnosus GG help with Antibiotic-Associated Diarrhea (AAD)?
Based on 20 studies with 4,000 participants, there is strong evidence from multiple clinical trials that Lactobacillus rhamnosus GG may support Antibiotic-Associated Diarrhea (AAD) management. Our evidence grade is A (Strong Evidence).
How much Lactobacillus rhamnosus GG should I take for Antibiotic-Associated Diarrhea (AAD)?
Studies have used various dosages. A commonly studied range is 10-20 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus rhamnosus GG?
Reported side effects may include Mild gas and bloating during initial use (usually resolves in 1-2 weeks), Rare reports of bacteremia in severely immunocompromised individuals, Occasional loose stools during adjustment period, Very rare: systemic infection in critically ill patients with central venous catheters. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus rhamnosus GG and Antibiotic-Associated Diarrhea (AAD)?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 20 peer-reviewed studies with 4,000 total participants. The overall direction of effect is positive.
Related Evidence
に関する他の成分： Antibiotic-Associated Diarrhea (AAD)
Lactobacillus rhamnosus GG 他の症状・状態について
FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。